In addition to their effects on glucose metabolism, DPP4 inhibitors such as sitagliptin, vildagliptin, linagliptin and saxagliptin also inhibit the degradation of NPY, thereby increasing its blood concentration in healthy individuals and patients with type 2 diabetes mellitus [17–21]. Here, DPP4 is linked to type 2 diabetes mellitus.